Evidence map›Paper›PMID 39267121›Full record

ReviewTranslational neurodegeneration2024

Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson's disease.

Xuxiang Zhang, Heng Wu, Beisha Tang, Jifeng Guo

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational neurodegeneration, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xuxiang ZhangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Heng WuDepartment of Neurology, Multi-Omics Research Center for Brain Disorders, The First Affiliated Hospital, University of South China, Hengyang, 421001, China.
Beisha TangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Jifeng GuoDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China. guojifeng@csu.edu.cn.ORCID 0000-0002-3658-3928

Funding

Technology Major Project of Hunan Provincial Science and Technology Department 2021SK1010the Innovation-driven Team Project from Central South University 2020CX016the innovative team program from the Department of Science & Technology of Hunan Province 2019RS1010the National Key Plan for Scientific Research and Development of China 2021YFC2501204the National Natural Science Foundation of China 81873785the National Natural Science Foundation of China 81974202the National Natural Science Foundation of China 82071439the National Natural Science Foundation of China U20A20355
6 · The paper itself

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease. The development of PD is closely linked to genetic and environmental factors, with GBA1 variants being the most common genetic risk. Mutations in the GBA1 gene lead to reduced activity of the coded enzyme, glucocerebrosidase, which mediates the development of PD by affecting lipid metabolism (especially sphingolipids), lysosomal autophagy, endoplasmic reticulum, as well as mitochondrial and other cellular functions. Clinically, PD with GBA1 mutations (GBA1-PD) is characterized by particular features regarding the progression of symptom severity. On the therapeutic side, the discovery of the relationship between GBA1 variants and PD offers an opportunity for targeted therapeutic interventions. In this review, we explore the genotypic and phenotypic correlations, etiologic mechanisms, biomarkers, and therapeutic approaches of GBA1-PD and summarize the current state of research and its challenges.

Indexed as

BiomarkersGlucosylceramidaseParkinson DiseaseHumansMutationBiomarkersGBA protein, humanGlucosylceramidaseBiomarkerGaucher’s diseaseGlucocerebrosidaseMechanismsParkinson’s diseaseTherapy

Identifiers

PMID39267121
PMCPMC11391654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.